Thyme Care Revolutionizing Cancer Care with $95M Funding Boost
July 18, 2024, 9:43 am
Thyme Care, a game-changer in value-based cancer care, secures a whopping $95M in funding to expand its innovative platform and make waves in the healthcare industry.
Thyme Care, a leading player in the value-based cancer care arena, has just scored big with a $95M funding injection. The funding, spearheaded by Concord Health Partners and backed by heavyweights like CVS Health® Ventures and a16z Bio + Health, brings Thyme Care's total funding to an impressive $178M.
In a world where cancer care costs are soaring and patient outcomes are often uncertain, Thyme Care is stepping up to the plate with a fresh approach. By focusing on improving patient outcomes, reducing healthcare costs, and enhancing the overall patient experience, Thyme Care is making waves in the healthcare landscape.
With a comprehensive model that includes specialized cancer care navigation, advanced technology and data insights, and provider-led therapeutic interventions, Thyme Care is already showing promising results. Patients under Thyme Care's guidance have seen a significant $594 reduction in monthly costs compared to those in a control group.
But Thyme Care isn't just stopping there. The company has forged strong partnerships with Medicare Advantage and commercial payers, as well as participating in CMS's Enhancing Oncology Model (EOM) to take on financial risk for oncology populations. This strategic move is driving down costs and improving outcomes for patients.
Thyme Care's rapid growth and expansion plans are nothing short of impressive. With over half a billion dollars in medical spend under risk-based contracts and a goal to triple this figure in the next year, Thyme Care is on a mission to reshape the oncology landscape. The company has more than doubled its oncology partnerships in the past six months and is gearing up to expand its reach across the United States.
CEO Robin Shah is thrilled about the company's latest funding round, emphasizing the dedication and expertise of the team driving Thyme Care's mission forward. With unwavering support from investors, providers, and payer partners, Thyme Care is poised to revolutionize cancer care and make it more accessible and affordable for all.
Thyme Care, a leading player in the value-based cancer care arena, has just scored big with a $95M funding injection. The funding, spearheaded by Concord Health Partners and backed by heavyweights like CVS Health® Ventures and a16z Bio + Health, brings Thyme Care's total funding to an impressive $178M.
In a world where cancer care costs are soaring and patient outcomes are often uncertain, Thyme Care is stepping up to the plate with a fresh approach. By focusing on improving patient outcomes, reducing healthcare costs, and enhancing the overall patient experience, Thyme Care is making waves in the healthcare landscape.
With a comprehensive model that includes specialized cancer care navigation, advanced technology and data insights, and provider-led therapeutic interventions, Thyme Care is already showing promising results. Patients under Thyme Care's guidance have seen a significant $594 reduction in monthly costs compared to those in a control group.
But Thyme Care isn't just stopping there. The company has forged strong partnerships with Medicare Advantage and commercial payers, as well as participating in CMS's Enhancing Oncology Model (EOM) to take on financial risk for oncology populations. This strategic move is driving down costs and improving outcomes for patients.
Thyme Care's rapid growth and expansion plans are nothing short of impressive. With over half a billion dollars in medical spend under risk-based contracts and a goal to triple this figure in the next year, Thyme Care is on a mission to reshape the oncology landscape. The company has more than doubled its oncology partnerships in the past six months and is gearing up to expand its reach across the United States.
CEO Robin Shah is thrilled about the company's latest funding round, emphasizing the dedication and expertise of the team driving Thyme Care's mission forward. With unwavering support from investors, providers, and payer partners, Thyme Care is poised to revolutionize cancer care and make it more accessible and affordable for all.